Phase I, dose-escalating study of elisidepsin (Irvalec®), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors

Sanjay Goel, Santiago Viteri, Teresa Morán, Cinthya Coronado, Jorge Luis Iglesias Dios, Bernardo Miguel-Lillo, Eva M. Fernández-García, Rafael Rosell

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I, dose-escalating study of elisidepsin (Irvalec®), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences